Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Biologics

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1744719

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1744719

Glucagon-Like Peptide 1 Agonists

PUBLISHED:
PAGES: 375 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Glucagon-Like Peptide 1 Agonists Market to Reach US$22.1 Billion by 2030

The global market for Glucagon-Like Peptide 1 Agonists estimated at US$17.2 Billion in the year 2024, is expected to reach US$22.1 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2024-2030. Exenatide, one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$10.9 Billion by the end of the analysis period. Growth in the Liraglutide segment is estimated at 5.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.7 Billion While China is Forecast to Grow at 7.8% CAGR

The Glucagon-Like Peptide 1 Agonists market in the U.S. is estimated at US$4.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.5 Billion by the year 2030 trailing a CAGR of 7.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Glucagon-Like Peptide-1 (GLP-1) Agonists Market - Key Trends & Drivers Summarized

Why Are GLP-1 Agonists Reshaping the Landscape of Metabolic Disorder Therapies?

Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized the management of type 2 diabetes and obesity, two of the world’s most pervasive metabolic disorders. These drugs mimic the action of the endogenous GLP-1 hormone, enhancing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and reducing appetite. Unlike traditional antidiabetic medications, GLP-1 agonists offer the dual benefits of glycemic control and weight loss, making them attractive for a broader patient population. Their role has expanded well beyond glucose management, with mounting clinical evidence demonstrating cardiovascular risk reduction, which has further solidified their place in treatment guidelines globally.

What distinguishes GLP-1 agonists is their mechanism of action that aligns closely with the pathophysiology of type 2 diabetes and obesity. These agents are now recommended as first-line or adjunct therapy for patients with comorbidities such as atherosclerotic cardiovascular disease, chronic kidney disease, or heart failure. Their injectable nature, once considered a barrier to adoption, has been addressed by newer formulations with weekly dosing and the recent approval of oral versions. With the growing global prevalence of diabetes and obesity, particularly in urbanized and aging populations, GLP-1 receptor agonists have become central to managing the dual epidemic of metabolic dysfunction and cardiovascular disease.

How Are Drug Innovations and Formulations Expanding Market Potential?

The GLP-1 agonist landscape is undergoing significant innovation, both in molecule development and formulation technologies. Second-generation agents such as semaglutide, tirzepatide (a dual GLP-1/GIP receptor agonist), and dulaglutide are setting new benchmarks for efficacy, tolerability, and patient adherence. Semaglutide, in particular, has demonstrated superior HbA1c reduction and weight loss compared to earlier analogs, leading to its approval for both diabetes (Ozempic) and chronic weight management (Wegovy). These advances are redefining treatment paradigms not only for diabetics but also for individuals with obesity and metabolic syndrome, irrespective of their diabetic status.

Pharmaceutical companies are heavily investing in long-acting formulations, oral bioavailability improvements, and fixed-dose combination products. The approval of oral semaglutide marked a major breakthrough, addressing the psychological and logistical barriers associated with injectable therapies. Additionally, combination therapies that integrate GLP-1 agonists with SGLT2 inhibitors or basal insulin are being explored to offer comprehensive metabolic management with fewer side effects. Pipelines are rich with next-generation dual and triple agonists targeting GLP-1, GIP, and glucagon receptors, offering synergistic benefits in weight reduction and insulin sensitivity. These innovations are expanding both the clinical utility and commercial scope of GLP-1-based treatments.

What Trends Are Reshaping Market Dynamics and Access to GLP-1 Therapies?

The strong demand for GLP-1 agonists is driving structural changes across the pharmaceutical supply chain, payor models, and patient engagement strategies. One significant trend is the surging off-label demand for weight loss, especially among non-diabetic populations, which has led to global supply constraints and rationing in some markets. The growing perception of GLP-1 agonists as lifestyle-enhancing drugs-amplified by social media, celebrity endorsements, and wellness influencers-has increased public awareness and reshaped consumer behavior. This is pushing regulatory agencies and healthcare systems to revisit policies on drug reimbursement and clinical eligibility.

Market access remains a major challenge, particularly in developing economies, where the high cost of GLP-1 agonists limits patient uptake. However, biosimilar development and generic competition are expected to influence pricing dynamics by the end of the decade. Another important trend is the integration of digital health technologies, such as connected devices and mobile health apps, which are being paired with GLP-1 treatments to improve adherence, monitor outcomes, and deliver personalized interventions. Additionally, insurers and employers are showing increased interest in covering GLP-1 therapies as part of broader disease management programs aimed at reducing long-term healthcare costs linked to obesity and diabetes.

What Is Driving the Rapid Expansion of the GLP-1 Agonists Market Across Therapeutic Frontiers?

The growth in the GLP-1 agonists market is driven by several factors directly related to drug innovation, expanding therapeutic indications, and shifting healthcare priorities. The increasing prevalence of type 2 diabetes and obesity, combined with the superior efficacy and safety profile of GLP-1 agonists compared to older therapies, is accelerating first-line adoption worldwide. Regulatory approvals for weight management-independent of diabetes status-have opened an entirely new therapeutic frontier, tapping into a vast and previously underserved global patient base.

Moreover, the success of agents like semaglutide and tirzepatide in reducing cardiovascular risk and achieving substantial weight loss has strengthened physician confidence and patient demand. Advances in drug delivery, including oral formulations and once-weekly dosing, are improving patient convenience and adherence, further supporting market penetration. The pipeline of next-generation dual and triple receptor agonists promises even greater clinical impact, particularly in addressing complex metabolic diseases like non-alcoholic steatohepatitis (NASH). Finally, rising payer interest in outcome-driven therapies, coupled with growing public awareness of metabolic health, is accelerating reimbursement pathways and market access for GLP-1 agonists across both developed and emerging healthcare systems.

SCOPE OF STUDY:

The report analyzes the Glucagon-Like Peptide 1 Agonists market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Exenatide, Liraglutide, Lixisenatide, Dulaglutide); Administration Route (Oral, Parenteral, Other Administration Routes); End-Use (Hospitals, Specialty Clinics, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • Altimmune, Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Boehringer Ingelheim GmbH
  • Crinetics Pharmaceuticals, Inc.
  • Eccogene Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • Hanmi Pharmaceutical Co., Ltd.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Terns Pharmaceuticals, Inc.
  • Veru Inc.
  • Viking Therapeutics, Inc.
  • Zealand Pharma A/S
  • Zydus Lifesciences Limited

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

Show more
Product Code: MCP35129

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Glucagon-Like Peptide 1 Agonists - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Type 2 Diabetes Drives Widespread Adoption of GLP-1 Agonist Therapies
    • Surge in Obesity Rates Across Key Markets Expands Addressable Population for GLP-1-Based Weight Management Drugs
    • Increasing Use of GLP-1 Agonists as First-Line Therapy Spurs Market Share Shift Away from Traditional Antidiabetics
    • Favorable Cardiovascular Outcomes Data Strengthens the Clinical Case for Expanded Use of GLP-1 Agonists
    • Growing Physician Preference for Weekly and Once-Daily Dosing Options Fuels Uptake of Long-Acting Formulations
    • FDA Approvals for Weight Loss Indications Propel Growth in Non-Diabetic Patient Populations
    • Integration of GLP-1 Agonists into Obesity Care Pathways Accelerates Demand Beyond Traditional Diabetes Use
    • Expansion of Combination Therapies with SGLT2 Inhibitors and Insulins Enhances Therapeutic Flexibility
    • Increased Payer Acceptance and Reimbursement Coverage Strengthens Market Access for GLP-1 Drugs
    • Pipeline Innovation in Oral GLP-1 Formulations Reduces Dependence on Injectable Delivery Systems
    • Rising Consumer Awareness of Metabolic Health Enhances Direct-to-Patient Demand for Weight Control Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Glucagon-Like Peptide 1 Agonists Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Glucagon-Like Peptide 1 Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Exenatide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Exenatide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Exenatide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Liraglutide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Liraglutide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Liraglutide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Lixisenatide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Lixisenatide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Lixisenatide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Dulaglutide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Dulaglutide by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Dulaglutide by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • JAPAN
    • Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • CHINA
    • Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • EUROPE
    • Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Glucagon-Like Peptide 1 Agonists by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • FRANCE
    • Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: France 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • GERMANY
    • Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Germany 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Italy 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: UK 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 119: Spain Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Spain Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Spain 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 128: Russia Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Russia Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Russia 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Europe 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Glucagon-Like Peptide 1 Agonists by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 158: Australia Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Australia Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Australia 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • INDIA
    • Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 167: India Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: India Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: India 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 170: India Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 176: South Korea Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: South Korea Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: South Korea 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of Asia-Pacific Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Glucagon-Like Peptide 1 Agonists by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 206: Argentina Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Argentina Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Argentina 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 215: Brazil Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Brazil Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Brazil 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 224: Mexico Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Mexico Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Mexico 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Latin America Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Latin America 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Glucagon-Like Peptide 1 Agonists by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 254: Iran Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Iran Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Iran 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 263: Israel Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Israel Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Israel 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Saudi Arabia Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Saudi Arabia 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 281: UAE Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: UAE Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: UAE 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Rest of Middle East Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Rest of Middle East 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030
  • AFRICA
    • Glucagon-Like Peptide 1 Agonists Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 299: Africa Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Africa Historic Review for Glucagon-Like Peptide 1 Agonists by Drug Type - Exenatide, Liraglutide, Lixisenatide and Dulaglutide Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Africa 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Drug Type - Percentage Breakdown of Value Sales for Exenatide, Liraglutide, Lixisenatide and Dulaglutide for the Years 2015, 2025 & 2030
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Glucagon-Like Peptide 1 Agonists by End-Use - Other End-Uses, Hospitals and Specialty Clinics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by End-Use - Percentage Breakdown of Value Sales for Other End-Uses, Hospitals and Specialty Clinics for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Glucagon-Like Peptide 1 Agonists by Administration Route - Oral, Parenteral and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Glucagon-Like Peptide 1 Agonists by Administration Route - Percentage Breakdown of Value Sales for Oral, Parenteral and Other Administration Routes for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!